Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Katharina Beyer; Lisa Moris; Michael Lardas; Anna Haire; Francesco Barletta; Simone Scuderi; Eleni Vradi; Giorgio Gandaglia; Muhammad Imran Omar; Steven MacLennan; Jihong Zong; Bahman Farahmand; Sara J. MacLennan; Zsuzsanna Devecseri; Alex Asiimwe; Laurence Collette; Anders Bjartell; James N'Dow; Alberto Briganti; Mieke Van Hemelrijck; The PIONEER Consortium

doi:10.1136/bmjopen-2020-040531

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Katharina Beyer^* (Corresponding Author), Lisa Moris, Michael Lardas, Anna Haire, Francesco Barletta, Simone Scuderi, Eleni Vradi, Giorgio Gandaglia, Muhammad Imran Omar, Steven MacLennan, Jihong Zong, Bahman Farahmand, Sara J. MacLennan, Zsuzsanna Devecseri, Alex Asiimwe, Laurence Collette, Anders Bjartell, James N'Dow, Alberto Briganti, Mieke Van HemelrijckThe PIONEER Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

12 Downloads (Pure)

Abstract

Introduction: As part of the PIONEER Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).
Methods and analysis: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) Risk of bias assessment and applicability with PROBAST (Prediction model Risk Of Bias Assessment Tool) criteria, QUADAS-2 and QUIPS; (4) additional quantitative assessments if required.
Ethics and Dissemination: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

Original language	English
Article number	e040531
Number of pages	5
Journal	BMJ Open
Volume	11
Issue number	2
Early online date	11 Feb 2021
DOIs	https://doi.org/10.1136/bmjopen-2020-040531
Publication status	Published - 2021

Bibliographical note

Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Keywords

Prostate cancer
diagnostic factor
prognostic factors
Urological tumours
Prostate disease
Oncology
BIAS
RISK
oncology
PROBAST
APPLICABILITY
urological tumours
TOOL
prostate disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmjopen-2020-040531Licence: CC BY

Beyer_DiagnosticPrognosticProstrateCancer_VOR
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Final published version, 677 KBLicence: CC BY

Cite this

Beyer, K., Moris, L., Lardas, M., Haire, A., Barletta, F., Scuderi, S., Vradi, E., Gandaglia, G., Omar, M. I., MacLennan, S., Zong, J., Farahmand, B., MacLennan, S. J., Devecseri, Z., Asiimwe, A., Collette, L., Bjartell, A., N'Dow, J., Briganti, A., ... The PIONEER Consortium (2021). Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 11(2), Article e040531. https://doi.org/10.1136/bmjopen-2020-040531

Beyer, K, Moris, L, Lardas, M, Haire, A, Barletta, F, Scuderi, S, Vradi, E, Gandaglia, G, Omar, MI , MacLennan, S, Zong, J, Farahmand, B, MacLennan, SJ, Devecseri, Z, Asiimwe, A, Collette, L, Bjartell, A, N'Dow, J, Briganti, A, Van Hemelrijck, M & The PIONEER Consortium 2021, 'Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol', BMJ Open, vol. 11, no. 2, e040531. https://doi.org/10.1136/bmjopen-2020-040531

@article{b063cbdb59444fb6ae2e5d8489537e79,

title = "Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol",

abstract = "Introduction: As part of the PIONEER Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) Risk of bias assessment and applicability with PROBAST (Prediction model Risk Of Bias Assessment Tool) criteria, QUADAS-2 and QUIPS; (4) additional quantitative assessments if required.Ethics and Dissemination: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.",

keywords = "Prostate cancer, diagnostic factor, prognostic factors, Urological tumours, Prostate disease, Oncology, BIAS, RISK, oncology, PROBAST, APPLICABILITY, urological tumours, TOOL, prostate disease",

author = "Katharina Beyer and Lisa Moris and Michael Lardas and Anna Haire and Francesco Barletta and Simone Scuderi and Eleni Vradi and Giorgio Gandaglia and Omar, {Muhammad Imran} and Steven MacLennan and Jihong Zong and Bahman Farahmand and MacLennan, {Sara J.} and Zsuzsanna Devecseri and Alex Asiimwe and Laurence Collette and Anders Bjartell and James N'Dow and Alberto Briganti and {Van Hemelrijck}, Mieke and {The PIONEER Consortium}",

note = "Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).",

year = "2021",

doi = "10.1136/bmjopen-2020-040531",

language = "English",

volume = "11",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "2",

}

TY - JOUR

T1 - Diagnostic and prognostic factors in patients with prostate cancer

T2 - a systematic review protocol

AU - Beyer, Katharina

AU - Moris, Lisa

AU - Lardas, Michael

AU - Haire, Anna

AU - Barletta, Francesco

AU - Scuderi, Simone

AU - Vradi, Eleni

AU - Gandaglia, Giorgio

AU - Omar, Muhammad Imran

AU - MacLennan, Steven

AU - Zong, Jihong

AU - Farahmand, Bahman

AU - MacLennan, Sara J.

AU - Devecseri, Zsuzsanna

AU - Asiimwe, Alex

AU - Collette, Laurence

AU - Bjartell, Anders

AU - N'Dow, James

AU - Briganti, Alberto

AU - Van Hemelrijck, Mieke

AU - The PIONEER Consortium

N1 - Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

PY - 2021

Y1 - 2021

N2 - Introduction: As part of the PIONEER Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) Risk of bias assessment and applicability with PROBAST (Prediction model Risk Of Bias Assessment Tool) criteria, QUADAS-2 and QUIPS; (4) additional quantitative assessments if required.Ethics and Dissemination: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

AB - Introduction: As part of the PIONEER Consortium, we will explore which diagnostic and prognostic factors (DPFs) are currently being researched to previously defined clinical and patient-reported outcomes for prostate cancer (PCa).Methods and analysis: This research project will follow the following four steps: (1) a broad systematic literature review of DPFs for all stages of PCa, covering evidence from 2014 onwards; (2) discussion of systematic review findings by a multidisciplinary expert panel; (3) Risk of bias assessment and applicability with PROBAST (Prediction model Risk Of Bias Assessment Tool) criteria, QUADAS-2 and QUIPS; (4) additional quantitative assessments if required.Ethics and Dissemination: We aim to develop an online tool to present the DPFs identified in this research and make them available across all stakeholders. There are no ethical implications.

KW - Prostate cancer

KW - diagnostic factor

KW - prognostic factors

KW - Urological tumours

KW - Prostate disease

KW - Oncology

KW - BIAS

KW - RISK

KW - oncology

KW - PROBAST

KW - APPLICABILITY

KW - urological tumours

KW - TOOL

KW - prostate disease

UR - http://www.scopus.com/inward/record.url?scp=85100831811&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-040531

DO - 10.1136/bmjopen-2020-040531

M3 - Article

C2 - 33574142

SN - 2044-6055

VL - 11

JO - BMJ Open

JF - BMJ Open

IS - 2

M1 - e040531

ER -

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this